The publication of the updated individual patient data meta-analysis of the larger randomised trials of intravenous rt-PA for acute ischaemic stroke has re-opened the debate about how the treatment should be used in routine practice, and what information can be expected to emerge in the next 2-3 years from the ongoing trials [the largest of which is the Third International Stroke Trial (IST-3)].
Get full access to this article
View all access options for this article.
References
1.
LeesKRBluhmkiEvon KummerR. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet2010; 375:1695–703.
2.
HackeWDonnanGFieschiC. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet2004; 363:768–74.
3.
Leys D, Ringelstein EB, Kaste M, Hacke W, for the Executive Committee of the European Stroke Initiative. Facilities available in European Hospitals Treating Stroke Patients. Stroke2007; 38:2985–91.
4.
FordGASandercockPAG. Current controversies: thrombolysis for patients with acute ischaemic stroke aged over 80. J Roy Coll Phys Edinburgh2010; 40:49–53.
5.
MishraNKLeesKWahlgrenNAhmedNAndersonGDavalosA. Outcomes after thrombolysis amongst patients aged> = 80 years and patients having diabetes or previous stroke: a synopsis. Cerebrovasc Dis2010; 29(Suppl. 2).
6.
SanossianNOvbiageleB. Prevention and management of stroke in very elderly patients. Lancet Neurol2009; 8:1031–41.
7.
WhiteleyWLindleyRWardlawJSandercockP. International Stroke Trial Collaborative Group. Third international stroke trial. Int J Stroke2006; 1:172–6.
8.
EngelterSTBonatiLHLyrerPA. Intravenous thrombolysis in stroke patients of>or = 80 versus<80 years of age–a systematic review across cohort studies. Age Ageing2006; 35:572–80.
